Denali Therapeutics Inc. DNLI
Set alert
19.14 USD +0.28 +1.48%
As of Nov 3, 9:30 AM ET
18.32 Day range 19.20
13.75 52-week range 27.30
- YTD
- +15.93%
- 1 year
- +24.61%
- Open
- 19.11
- Prev close
- 18.86
- Mkt cap
- 3.01B
- Vol
- 17.32K
- Avg vol
- 1.57M
- EPS
- -2.84
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 18.32
- High
- 19.20
- Forward P/E
- -7.80
- Beta
- 1.08
- Short ratio
- 7.76
- Inst. own
- 101.31%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 20.64
- 200-d avg
- 21.23
- 1y target
- 35.50
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 35.50 +85.5% upside
Now 19.14
- Target (low)
- 23.00
- Target (mean)
- 35.50
- Target (high)
- 42.00
Ratings (0m) 20 19 buy · 1 hold · 0 sell
- Strong buy2
- Buy17
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 20
- 1 month ago 20
- 2 months ago 20
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.36666 | -0.88 – 0.38 | -0.74 | +50.5% | 22.90M | 0.0% | 17 |
| Next quarter | -0.62296 | -0.80 – -0.45988 | -0.73 | +14.7% | 24.53M | 0.0% | 17 |
| Current year | -2.23 | -2.75 – -0.22 | -2.97 | +25.0% | 50.65M | 0.0% | 17 |
| Next year | -2.42 | -3.20 – -1.70 | -2.23 | -8.5% | 130.64M | +157.9% | 17 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 25, 2026 | B. Riley Securities | Maintained | Buy | Buy |
| Aug 7, 2026 | UBS | Maintained | Buy | Buy |
| Jul 23, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jul 16, 2026 | Deutsche Bank | Maintained | Buy | Buy |
| May 26, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| May 14, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| May 11, 2026 | BTIG | Reiterated | Buy | Buy |
| May 8, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Apr 22, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Apr 7, 2026 | Baird | Maintained | Outperform | Outperform |
| Mar 26, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Mar 26, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Mar 26, 2026 | Stifel | Maintained | Buy | Buy |
| Mar 26, 2026 | Baird | Maintained | Outperform | Outperform |
| Mar 26, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 25, 2026 | BTIG | Maintained | Buy | Buy |
| Mar 2, 2026 | BTIG | Maintained | Buy | Buy |
| Feb 24, 2026 | Wolfe Research | Initiated | — | Peer Perform |
| Feb 6, 2026 | BTIG | Reiterated | Buy | Buy |
| Dec 11, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Dec 5, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Dec 5, 2025 | BTIG | Reiterated | Buy | Buy |
| Nov 4, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Sep 8, 2025 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Aug 18, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| May 19, 2025 | B of A Securities | Maintained | Buy | Buy |
| May 8, 2025 | Baird | Maintained | Outperform | Outperform |
| May 7, 2025 | Wedbush | Maintained | Outperform | Outperform |
| May 7, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 10, 2025 | B of A Securities | Maintained | Buy | Buy |